InterMune Inc.
3280 Bayshore Boulevard
Brisbane,
CA 94005
United States - Map
Phone: 415-466-2200
Fax: 415-466-2300
Web Site: http://www.intermune.com
| InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH. The company was founded in 1998 and is headquartered in Brisbane, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Daniel G. Welch , 51
Chairman, Chief Exec. Officer, Pres and Member of Special Bus. Devel./Fin. Committee |
$
1.10M |
$
0 | Mr. John C. Hodgman B.S., M.B.A., 54
Chief Financial Officer and Sr. VP of Fin. |
$
628.00K |
$
0 | Dr. Steven B. Porter M.D.,Ph.D., 52
Chief Medical Officer |
$
712.00K |
$
0 | Dr. Marianne T. Armstrong Ph.D., 54
Chief Medical Affairs & Regulatory Officer |
$
702.00K |
$
0 | Dr. Malcolm McKay Ph.D., 53
VP of Corp. Compliance and Compliance Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.30 (2.72%) 
Profile
